Overexpression of salusin-β is associated with poor prognosis in ovarian cancer

Zhang,Qian; Chen,Wen-Ming; Zhang,Xin-Xin; Zhang,Hu-Xiang; Wang,Han-Chu; Zheng,Fei-Yun; Zhu,Fang-Fang

doi:10.3892/or.2017.5429

Overexpression of salusin-β is associated with poor prognosis in ovarian cancer

Authors:
- Qian Zhang
- Wen-Ming Chen
- Xin-Xin Zhang
- Hu-Xiang Zhang
- Han-Chu Wang
- Fei-Yun Zheng
- Fang-Fang Zhu
View Affiliations

Affiliations: Department of Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China, Department of Obstetrics and Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China, Department of Pathology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China
Published online on: February 7, 2017 https://doi.org/10.3892/or.2017.5429
Pages: 1826-1832

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer is recognized as one of the worst gynecologic malignancies associated with rapid metastasis and poor overall survival rate. The identified valuable molecular biomarkers criticize importance of timely diagnosis for ovarian cancer. Salusin-β levels are dramatically increased in women with polycystic ovarian syndrome. However, the roles of salusin-β in ovarian cancer have yet to be fully elucidated. A total of 57 paired ovarian cancer specimens and matched adjacent normal tissues were used to measure the salusin-β levels. The prognostic value of salusin-β for tumor progression and survival rate was investigated. The effects of salusin-β on ovarian cancer cell proliferation and epithelial-mesenchymal transition were also explored. The expression of salusin-β was significantly increased in ovarian cancer tissue specimens compared with matched normal adjacent tissue (P<0.05). The high salusin-β level was closely related with FIGO stage and lymph node metastases. The ovarian cancer patients with high salusin-β had a shorter overall survival (P<0.05). Salusin-β obviously enhanced the proliferation and epithelial mesenchymal-transition of SKOV3 cells. Furthermore, salusin-β substantially decreased the expression of p-GSK-3β and GSK-3β, but stimulated the β-catenin expression and downstream genes of wnt/β-catenin including cyclin D1 and C-myc. Our data demonstrated for the first time that upregulated salusin-β may be a novel independent prognostic biomarker for overall survival of ovarian cancer. Salusin-β accelerated the proliferation and epithelial mesenchymal transition of ovarian cancer cells at least partly via activation of Wnt/β-catenin signaling pathway. Salusin-β may be an important target for therapeutic intervention in ovarian cancer.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
3	Ma M and Yu N: Ubiquitin-specific protease 7 expression is a prognostic factor in epithelial ovarian cancer and correlates with lymph node metastasis. Onco Targets Ther. 9:1559–1569. 2016.PubMed/NCBI
4	Zhao GY, Lin ZW, Lu CL, Gu J, Yuan YF, Xu FK, Liu RH, Ge D and Ding JY: USP7 overexpression predicts a poor prognosis in lung squamous cell carcinoma and large cell carcinoma. Tumour Biol. 36:1721–1729. 2015. View Article : Google Scholar : PubMed/NCBI
5	Holschneider CH and Berek JS: Ovarian cancer: Epidemiology, biology, and prognostic factors. Semin Surg Oncol. 19:3–10. 2000. View Article : Google Scholar : PubMed/NCBI
6	Nathan JA, Sengupta S, Wood SA, Admon A, Markson G, Sanderson C and Lehner PJ: The ubiquitin E3 ligase MARCH7 is differentially regulated by the deubiquitylating enzymes USP7 and USP9X. Traffic. 9:1130–1145. 2008. View Article : Google Scholar : PubMed/NCBI
7	Jelovac D and Armstrong DK: Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 61:183–203. 2011. View Article : Google Scholar : PubMed/NCBI
8	Zhang X and Zhang H: Diminished miR-613 expression as a novel prognostic biomarker for human ovarian cancer. Eur Rev Med Pharmacol Sci. 20:837–841. 2016.PubMed/NCBI
9	Shichiri M, Ishimaru S, Ota T, Nishikawa T, Isogai T and Hirata Y: Salusins: Newly identified bioactive peptides with hemodynamic and mitogenic activities. Nat Med. 9:1166–1172. 2003. View Article : Google Scholar : PubMed/NCBI
10	Celik E, Celik O, Yilmaz E, Turkcuoglu I, Karaer A, Turhan U and Aydin S: Association of low maternal levels of salusins with gestational diabetes mellitus and with small-for-gestational-age fetuses. Eur J Obstet Gynecol Reprod Biol. 167:29–33. 2013. View Article : Google Scholar : PubMed/NCBI
11	Sato K, Watanabe R, Itoh F, Shichiri M and Watanabe T: Salusins: Potential use as a biomarker for atherosclerotic cardiovascular diseases. Int J Hypertens. 2013:9651402013. View Article : Google Scholar : PubMed/NCBI
12	Olson SH, Carlson MD, Ostrer H, Harlap S, Stone A, Winters M and Ambrosone CB: Genetic variants in SOD2, MPO, and NQO1, and risk of ovarian cancer. Gynecol Oncol. 93:615–620. 2004. View Article : Google Scholar : PubMed/NCBI
13	Celik Ö, Yılmaz E, Celik N, Minareci Y, Turkcuoglu I, Simsek Y, Celik E, Karaer A and Aydin S: Salusins, newly identified regulators of hemodynamics and mitogenesis, increase in polycystic ovarian syndrome. Gynecol Endocrinol. 29:83–86. 2013. View Article : Google Scholar : PubMed/NCBI
14	Sahin L, Bozkurt M, Celik O, Celik N, Aydin S and Gencdal S: Serum salusins levels are increased and correlated positively with cyst size in ovarian endometrioma. Gynecol Endocrinol. 31:639–642. 2015. View Article : Google Scholar : PubMed/NCBI
15	Sun HJ, Zhao MX, Ren XS, Liu TY, Chen Q, Li YH, Kang YM, Wang JJ and Zhu GQ: Salusin-beta promotes vascular smooth muscle cell migration and intimal hyperplasia after vascular injury via ROS/NFkappaB/MMP-9 pathway. Antioxid Redox Signa. 24:1045–1057. 2016. View Article : Google Scholar
16	Sun HJ, Liu TY, Zhang F, Xiong XQ, Wang JJ, Chen Q, Li YH, Kang YM, Zhou YB, Han Y, et al: Salusin-β contributes to vascular remodeling associated with hypertension via promoting vascular smooth muscle cell proliferation and vascular fibrosis. Biochim Biophys Acta. 1852:1709–1718. 2015. View Article : Google Scholar : PubMed/NCBI
17	Sun HJ, Zhang LL, Fan ZD, Chen D, Zhang L, Gao XY, Kang YM and Zhu GQ: Superoxide anions involved in sympathoexcitation and pressor effects of salusin-β in paraventricular nucleus in hypertensive rats. Acta Physiol (Oxf). 210:534–545. 2014. View Article : Google Scholar : PubMed/NCBI
18	Wang S and Liu W: Paeoniflorin inhibits proliferation and promotes apoptosis of multiple myeloma cells via its effects on microRNA-29b and matrix metalloproteinase-2. Mol Med Rep. 14:2143–2149. 2016.PubMed/NCBI
19	Chen J, Wang S, Su J, Chu G, You H, Chen Z, Sun H, Chen B and Zhou M: Interleukin-32α inactivates JAK2/STAT3 signaling and reverses interleukin-6-induced epithelial-mesenchymal transition, invasion, and metastasis in pancreatic cancer cells. Onco Targets Ther. 9:4225–4237. 2016. View Article : Google Scholar : PubMed/NCBI
20	Shan S, Lv Q, Zhao Y, Liu C, Sun Y, Xi K, Xiao J and Li C: Wnt/β-catenin pathway is required for epithelial to mesenchymal transition in CXCL12 over expressed breast cancer cells. Int J Clin Exp Pathol. 8:12357–12367. 2015.PubMed/NCBI
21	Xiao C, Wu CH and Hu HZ: LncRNA UCA1 promotes epithelial-mesenchymal transition (EMT) of breast cancer cells via enhancing Wnt/beta-catenin signaling pathway. Eur Rev Med Pharmacol Sci. 20:2819–2824. 2016.PubMed/NCBI
22	Cong J, Liu R, Wang X, Wang J, Wang H and Hou J: Low miR-498 expression levels are associated with poor prognosis in ovarian cancer. Eur Rev Med Pharmacol Sci. 19:4762–4765. 2015.PubMed/NCBI
23	Wan WN, Zhang YQ, Wang XM, Liu YJ, Zhang YX, Que YH, Zhao WJ and Li P: Down-regulated miR-22 as predictive biomarkers for prognosis of epithelial ovarian cancer. Diagn Pathol. 9:1782014. View Article : Google Scholar : PubMed/NCBI
24	Ren P, Yang XQ, Zhai XL, Zhang YQ and Huang JF: Overexpression of Rab27B is correlated with distant metastasis and poor prognosis in ovarian cancer. Oncol Lett. 12:1539–1545. 2016.PubMed/NCBI
25	Niepolski L and Grzegorzewska AE: Salusins and adropin: New peptides potentially involved in lipid metabolism and atherosclerosis. Adv Med Sci. 61:282–287. 2016. View Article : Google Scholar : PubMed/NCBI
26	Xu T, Zhang Z, Liu T, Zhang W, Liu J, Wang W and Wang J: Salusin-β contributes to vascular inflammation associated with pulmonary arterial hypertension in rats. J Thorac Cardiovasc Surg. 152:1177–1187. 2016. View Article : Google Scholar : PubMed/NCBI
27	Liu J, Ren YG, Zhang LH, Tong YW and Kang L: Serum salusin-beta levels are associated with the presence and severity of coronary artery disease. J Investig Med. 63:632–635. 2015. View Article : Google Scholar : PubMed/NCBI
28	Hu X and Sun S: RAD51 Gene 135G/C polymorphism and ovarian cancer risk: A meta-analysis. Int J Clin Exp Med. 8:22365–22370. 2015.PubMed/NCBI
29	Liu X and Li G: MicroRNA-133b inhibits proliferation and invasion of ovarian cancer cells through Akt and Erk1/2 inactivation by targeting epidermal growth factor receptor. Int J Clin Exp Pathol. 8:10605–10614. 2015.PubMed/NCBI
30	Diepenbruck M and Christofori G: Epithelial-mesenchymal transition (EMT) and metastasis: Yes, no, maybe? Curr Opin Cell Biol. 43:7–13. 2016. View Article : Google Scholar : PubMed/NCBI
31	Xu Q, Deng F, Qin Y, Zhao Z, Wu Z, Xing Z, Ji A and Wang QJ: Long non-coding RNA regulation of epithelial-mesenchymal transition in cancer metastasis. Cell Death Dis. 7:e22542016. View Article : Google Scholar : PubMed/NCBI
32	Kypta RM and Waxman J: Wnt/β-catenin signalling in prostate cancer. Nat Rev Urol. 9:418–428. 2012. View Article : Google Scholar : PubMed/NCBI
33	Yoshida S, Furukawa N, Haruta S, Tanase Y, Kanayama S, Noguchi T, Sakata M, Yamada Y, Oi H and Kobayashi H: Expression profiles of genes involved in poor prognosis of epithelial ovarian carcinoma: a review. Int J Gynecol Cancer. 19:992–997. 2009. View Article : Google Scholar : PubMed/NCBI
34	Arend RC, Londoño-Joshi AI, Straughn JM Jr and Buchsbaum DJ: The Wnt/β-catenin pathway in ovarian cancer: A review. Gynecol Oncol. 131:772–779. 2013. View Article : Google Scholar : PubMed/NCBI
35	Boone JD, Arend RC, Johnston BE, Cooper SJ, Gilchrist SA, Oelschlager DK, Grizzle WE, McGwin G Jr, Gangrade A, Straughn JM Jr, et al: Targeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974. Lab Invest. 96:249–259. 2016. View Article : Google Scholar : PubMed/NCBI
36	Liu H, Shi H, Fan Q and Sun X: Cyclin Y regulates the proliferation, migration, and invasion of ovarian cancer cells via Wnt signaling pathway. Tumour Biol. 37:10161–10175. 2016. View Article : Google Scholar : PubMed/NCBI
37	Bernaudo S, Salem M, Qi X, Zhou W, Zhang C, Yang W, Rosman D, Deng Z, Ye G, Yang B, et al: Cyclin G2 inhibits epithelial-to-mesenchymal transition by disrupting Wnt/β-catenin signaling. Oncogene. 35:4816–4827. 2016. View Article : Google Scholar : PubMed/NCBI